Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials
Key takeaways
- Natera (NTRA), Cyto Dyn Announce Strategic Collaboration for ct DNA-Guided m CRC Clinical Trials Maham Fatima Wed, June 17, 2026 at 8:45 PM GMT+7 2 min read NTRA Natera Inc.
- The partnership also grants CytoDyn access to Natera Inc.’s (NASDAQ:NTRA) proprietary oncology database, which integrates molecular response data with curated electronic medical records.
- This collaboration follows the completion of enrollment for the CLOVER study, which is investigating leronlimab in combination with standard therapies for previously treated mCRC patients.
Natera (NTRA), Cyto Dyn Announce Strategic Collaboration for ct DNA-Guided m CRC Clinical Trials Maham Fatima Wed, June 17, 2026 at 8:45 PM GMT+7 2 min read NTRA Natera Inc. (NASDAQ:NTRA) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On June 4, Natera and Cyto Dyn entered a strategic collaboration to utilize ct DNA-guided insights and molecular response analysis for Cyto Dyn’s metastatic colorectal cancer (m CRC) development program. Under the agreement, Natera will use its Signatera personalized MRD assay to evaluate clinical trial samples from CytoDyn’s CLOVER Phase 2 study, focusing on ctDNA dynamics and response patterns linked to the monoclonal antibody leronlimab.
The partnership also grants CytoDyn access to Natera Inc.’s (NASDAQ:NTRA) proprietary oncology database, which integrates molecular response data with curated electronic medical records. By leveraging this large-scale multimodal dataset, the companies aim to analyze treatment patterns and disease progression to better inform future clinical trial designs, biomarker-driven patient selection, and overall development strategies for leronlimab.
This collaboration follows the completion of enrollment for the CLOVER study, which is investigating leronlimab in combination with standard therapies for previously treated mCRC patients. Both companies anticipate that these combined molecular and real-world insights will provide a deeper understanding of treatment response, potentially supporting the future expansion of leronlimab into additional solid tumor indications.